BTLA+CD200+ B cells dictate the divergent immune landscape and immunotherapeutic resistance in metastatic vs. primary pancreatic cancer (vol 41, pg 4349, 2022)

Diskin, B; Adam, S; Soto, GS; Liria, M; Aykut, B; Sundberg, B; Li, ER; Leinwand, J; Chen, RA; Kim, M; Salas, RD; Cassini, MF; Buttar, C; Wang, W; Farooq, MS; Shadaloey, SAA; Werba, G; Fnu, A; Yang, F; Hirsch, C; Glinski, J; Panjwani, A; Weitzner, Y; Cohen, D; Asghar, U; Miller, G

ONCOGENE, 2023; ():